Relmada Therapeutics (RLMD) Preferred Shares (2014 - 2015)
Relmada Therapeutics (RLMD) reported Preferred Shares of $72.0 for Q3 2015, down 97.84% year-over-year from $3337.0 in Q3 2014, and little changed quarter-over-quarter from $72.0 in Q2 2015.
Relmada Therapeutics (RLMD) Preferred Shares (2014 - 2015) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of Preferred Shares data on file, last reported at $72.0 in Q3 2015.
- Preferred Shares for Q3 2015 came in at $72.0, down 97.84% year-over-year; the trailing twelve-month figure through Sep 2015 was $72.0 (down 97.84% YoY), and the FY2015 annual result was $72.0, down 89.21% from the prior year.
- Preferred Shares held at $72.0 in Q3 2015 per RLMD's latest filing, from $72.0 in the prior quarter.
- Over five years, Preferred Shares peaked at $3337.0 in Q3 2014 and troughed at $72.0 in Q2 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 72.00 |
| Jun 30, 2015 | 72.00 |
| Mar 31, 2015 | 465.00 |
| Dec 31, 2014 | 465.00 |
| Sep 30, 2014 | 3,337.00 |
| Jun 30, 2014 | 667.00 |